Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

INDIANAPOLIS (AP) — Eli Lilly is dialing back its 2024 forecast after underwhelming Wall Street with third-quarter earnings and sales from two key drugs that missed expectations. The drugmaker ...

JPMorgan said Eli Lilly is enrolling about 500,000 new obesity drug patients per month, and maintains more than 60% share in ...

Eli Lilly (NYSE:LLY) recently received FDA approval for a new dosing schedule of Kisunla, aimed at reducing amyloid-related ...

AP Health Writer (AP) — Eli Lilly is dialing back its 2024 forecast after underwhelming Wall Street with third-quarter earnings and sales from two key drugs that missed expectations.